Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Invasive Bladder Cancer × Genitourinary × Clear all

Phase

Phase NA 3 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1298 Carcinoma, Renal Cell 513 Urinary Bladder Neoplasms 324 Kidney Neoplasms 228 Carcinoma, Transitional Cell 163 Neoplasm Metastasis 150 Neoplasms 106 Melanoma 72 Breast Neoplasms 70 Carcinoma, Non-Small-Cell Lung 69 Testicular Neoplasms 56 Ovarian Neoplasms 52 Sarcoma 48 Urethral Neoplasms 44 Wilms Tumor 43 Non-Muscle Invasive Bladder Neoplasms 42 Lung Neoplasms 39 Colorectal Neoplasms 37 Neuroblastoma 36 Pancreatic Neoplasms 33 Lymphoma, Non-Hodgkin 31 Penile Neoplasms 30 Urologic Neoplasms 28 Uterine Cervical Neoplasms 27 Recurrence 26 Osteosarcoma 26 Ureteral Neoplasms 24 Rhabdomyosarcoma 22 Head and Neck Neoplasms 22 Clear-cell metastatic renal cell carcinoma 22

Interventions

tremelimumab 1 durvalumab 1 Radiotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03702179 2024-12-05

IMMUNOPRESERVE

Spanish Oncology Genito-Urinary Group

Phase 2 Completed

32 enrolled 19 charts

Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡